Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Novel biologics to treat T cell mediated inflammatory disease

Description:

Biologic therapeutic approach to modulating T cell inflammatory diseases by expressing isolated or recombinant combinations of WSX-1 or gp130 polypeptide with interacting proteins (such as p28, EBI3, Il-27) to inhibit pathological T cell development. 

 

Problem

The interleukin-27 receptor (WSX -1) is a heterodimeric type I cytokine receptor for interleukin-27 comprising the WSX-1 (alpha subunit) and glycoprotein 130 and is essential for initiation of Th1 cell differentiation. 

 

 

Solution

Dr. Christopher Hunter discovered that WSX-1 signaling has a negative effect on T cell responses.  In fact a WSX-1 fusion protein or soluble p28 (Il-30) is able to enhance the ability of Il-27 to inhibit T cell production of Il-2 and IFNγ as well as the T cell subset of Il-17 producing T cells, which is a major pathological T cell subset.  Penn has pending proprietary rights to various polypeptide compositions which encompass this technology.

  

Advantages

Il-27 is a potent immune suppressive cytokine when given exogenously in multiple experimental models of immune mediated disease with clinical utility.

Unlike other cytokines, such as type I IFNs or IL-12, there is no overt toxicity when IL-27 is used to treat mice.

 

 

Inventor

Christopher Hunter 

 

Stage of Development

Preclinical proof of concept 

Intellectual Property

Pending application in Canada; issued patents in US, European Union, and Mexico 

 

Reference Media

Immunity. 2003 Nov; 19(5):645-55.

 

Desired partnerships

• License

Co-development

 

Download PDF

 

Docket #  S4226

 


Patent Information:
For Information, Contact:
Melissa Kelly
Associate Director, SEAS/SAS Licensing Group
University of Pennsylvania
215-898-9877
kellymel@upenn.edu
Inventors:
Christopher Hunter
Keywords: